M-110 is a highly selective, ATP-competitive PIM kinase inhibitor with the strongest inhibitory activity against PIM-3 (IC50 = 47 nM), and IC50 values of 2.5 μM for PIM-1 and PIM-2; it inhibits the proliferation of prostate cancer cells (DU-145, 22Rv1, PC3) and colon cancer SW480 cells with IC50 values ranging from 0.6 to 0.9 μM; M-110 suppresses STAT3 Tyr705 phosphorylation and downregulates active STAT3 expression via PIM-3 inhibition; it shows no cytotoxicity toward normal human peripheral blood mononuclear cells at concentrations up to 40 μM.